Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240735 | 1.00 | CA14 (0.34) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL4914499 | 0.94 | CA14 (0.37) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL2660690 | 0.91 | CA14 (0.33) | CA14NR1H2 | |
| SCHEMBL1238808 | 0.91 | CA14 (0.33) | CA14NR1H2 | |
| SCHEMBL6497271 | 0.89 | CA14 (0.36) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL4711748 | 0.89 | CA14 (0.39) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL6486782 | 0.88 | CA14 (0.35) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL6485797 | 0.87 | EPHX1 (0.35) | CA14TDP1HDAC1HDAC2HDAC6 | |
| SCHEMBL12750824 | 0.85 | CA12 (0.36) | CA14 | |
| SCHEMBL15285331 | 0.84 | CA14 (0.36) | CA14TDP1HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CA14 4062/4885TDP1 3294/4885HDAC1 2334/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CA14 4062/4885TDP1 3294/4885HDAC1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.